单位:[1]Capital Med Univ, Beijing Friendship Hosp, Dept Gen Surg, Beijing 100050, Peoples R China临床科室国家中心普外分中心普外五科(综合普外科)首都医科大学附属北京友谊医院[2]Capital Med Univ, Beijing Friendship Hosp, Beijing Key Lab Translat Med Liver Cirrhosis, Beijing 100050, Peoples R China首都医科大学附属北京友谊医院[3]Gen Hosp Chinese Peoples Armed Police Forces, Organ Transplantat Inst, Beijing 100039, Peoples R China
Identification of new biomarkers for aggressiveness of hepatocellular carcinoma (HCC) to supplement the current group of prognosis algorithms is a significant clinical need. To clarify expression levels of microRNA-744 (miR-744) in HCC tissues and to explore its clinicopathological significance in HCC patients following liver transplantation (LT), we quantified miR-744 using real-time quantitative reverse transcription polymerase chain reaction in 96 paired cancerous tissues and para-cancerous normal liver tissues. We investigated relationships among miR-744 expression, clinicopathological parameters, and overall survival (OS). Of 96 paired samples, 68 cancer tissues expressed low miR-744 compared with their matched normal liver tissues. Patients with microvascular invasion or multi-tumor nodules showed significantly lower miR-744 expression; miR-744 was further decreased in patients with post-LT HCC recurrence compared with non-recurring patients. Patients with lower miR-744 expression showed significantly poorer recurrence-free survival and OS than individuals with higher miR-744 levels. Multivariate analysis revealed that lower miR-744 was an independent predictor of poor prognosis. Our results associate decreased miR-744 expression with HCC recurrence and prognosis, and also suggest that miR-744 is an independent predictor of survival in HCC patients after LT and may therefore be a potential biomarker for their prognosis. (C) 2014 Published by Elsevier Masson SAS.
基金:
Beijing Key Laboratory of Translational Medicine in Liver Cirrhosis, Beijing Friendship Hospital, Capital Medical University
第一作者单位:[1]Capital Med Univ, Beijing Friendship Hosp, Dept Gen Surg, Beijing 100050, Peoples R China
通讯作者:
通讯机构:[1]Capital Med Univ, Beijing Friendship Hosp, Dept Gen Surg, Beijing 100050, Peoples R China[*1]Capital Med Univ CCMU, Beijing Friendship Hosp, Dept Gen Surg, 95 Yong An Rd, Beijing 100050, Peoples R China
推荐引用方式(GB/T 7714):
Tan Yu-Le,Bai Zhi-Gang,Zou Wei-Long,et al.miR-744 is a potential prognostic marker in patients with hepatocellular carcinoma[J].CLINICS and RESEARCH in HEPATOLOGY and GASTROENTEROLOGY.2015,39(3):359-365.doi:10.1016/j.clinre.2014.09.010.
APA:
Tan, Yu-Le,Bai, Zhi-Gang,Zou, Wei-Long,Ma, Xue-Mei,Wang, Ting-Ting...&Zhang, Zhong-Tao.(2015).miR-744 is a potential prognostic marker in patients with hepatocellular carcinoma.CLINICS and RESEARCH in HEPATOLOGY and GASTROENTEROLOGY,39,(3)
MLA:
Tan, Yu-Le,et al."miR-744 is a potential prognostic marker in patients with hepatocellular carcinoma".CLINICS and RESEARCH in HEPATOLOGY and GASTROENTEROLOGY 39..3(2015):359-365